APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION FOR COAGULATION OF SUBCUTANEOUS SOFT TISSUES FOLLOWING LIPOSUCTION FOR AESTHETIC BODY CONTOURINGBy ApyxMedical|2025-12-12T19:03:25+00:00April 28, 2023|
APYX MEDICAL CORPORATION TO RELEASE FIRST QUARTER OF FISCAL YEAR 2023 FINANCIAL RESULTS ON MAY 11, 2023By ApyxMedical|2025-12-12T19:03:58+00:00April 5, 2023|
